天然痘:治療薬開発パイプライン分析

◆英語タイトル:Smallpox - Pipeline Review, H1 2018
◆商品コード:GMDHC10093IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2018年1月23日
◆ページ数:73
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥214,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥428,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥642,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界における天然痘の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。
・イントロダクション
・天然痘の概要
・天然痘治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・天然痘パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・企業別、開発中の製品
・大学/研究機関別、研究中の製品
・天然痘治療薬開発に取り組んでいる企業:企業別製品パイプライン
・天然痘治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Smallpox – Pipeline Review, H1 2018

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Smallpox – Pipeline Review, H1 2018, provides an overview of the Smallpox (Infectious Disease) pipeline landscape.

Smallpox is an acute contagious infection caused by the Variola virus. Symptoms include fever, malaise, headache, prostration, severe back pain, abdominal pain and vomiting. This is followed by the development of rashes on the face, hands, forearms and the trunk. Lesions develop in the mucous membranes of the nose and mouth which ulcerate, releasing large amounts of virus into the mouth and throat. Treatment includes medications such as antiviral and lifestyle modification.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Smallpox – Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Smallpox (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Smallpox (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Smallpox and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Preclinical and Discovery stages are 1, 2, 6 and 4 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Smallpox (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Smallpox (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Smallpox (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Smallpox (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Smallpox (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Smallpox (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Smallpox (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Smallpox (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Smallpox – Overview
Smallpox – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Smallpox – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Smallpox – Companies Involved in Therapeutics Development
Bavarian Nordic A/S
BioFactura Inc
CEL-SCI Corp
Chimerix Inc
EpiVax Inc
SIGA Technologies Inc
Tonix Pharmaceuticals Holding Corp
Smallpox – Drug Profiles
24a – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
brincidofovir – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CEL-1000 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
infectious disease vaccines – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies for Infectious Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody for Smallpox – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NN-001 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PL-801 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SCV-305 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
smallpox [ankara] vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
smallpox vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tecovirimat – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TNX-801 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VIR-002 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Smallpox – Dormant Projects
Smallpox – Discontinued Products
Smallpox – Product Development Milestones
Featured News & Press Releases
Dec 11, 2017: SIGA Technologies Announces FDA Submission of its New Drug Application for oral TPOXX (tecovirimat) to Treat Smallpox
Nov 21, 2017: Bavarian Nordic Announces Exercise of Clinical Option by the US Government under Contract for Freeze-dried IMVAMUNE Smallpox Vaccine
Sep 27, 2017: Bavarian Nordic Secures Contract Award for Supply of Freeze-dried IMVAMUNE Smallpox Vaccine to the U.S. Government
Sep 20, 2017: SIGA to Present at the Cantor Fitzgerald Global Healthcare Conference on September 27, 2017
Jun 16, 2017: Bavarian Nordic Announces Notification of Request for Proposal for Freeze-Dried IMVAMUNE
May 31, 2017: SIGA to Present at the Jefferies Global Healthcare Conference on June 9, 2017
Apr 20, 2017: SIGA Completes Enrollment and Dosing in Final Cohort of Phase I Study of IV Formulation of TPOXX (tecovirimat) to Treat Smallpox
Mar 02, 2017: Tonix Pharmaceuticals Announces Demonstrated Vaccine Activity in First-Ever Synthesized Chimeric Horsepox Virus
Jan 10, 2017: Tonix Pharmaceuticals Provides Update on TNX-801 at 9th Annual Biotech Showcase Conference
Jan 06, 2017: Chimerix Announces Preliminary Data from Ongoing Phase 1 Dose Escalation Study of Intravenous Brincidofovir in Healthy Subjects
Nov 23, 2016: Bavarian Nordic Completes Enrollment of Phase 3 Non-inferiority Study of IMVAMUNE Smallpox Vaccine
Sep 21, 2016: SIGA Announces Bankruptcy Court Approval of Transaction Under Which SIGA Will Pay PharmAthene Claim in Full
Jun 15, 2016: Bavarian Nordic Announces Expansion of IMVAMUNE Orders from Canadian Government
Feb 24, 2016: FDA Concurs on Clinical Dose for SIGA’s Tecovirimat Antiviral
Feb 08, 2016: Chimerix Presents Positive Results From Brincidofovir Pivotal Study in Animal Model for Smallpox
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Smallpox, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Smallpox - Pipeline by Bavarian Nordic A/S, H1 2018
Smallpox - Pipeline by BioFactura Inc, H1 2018
Smallpox - Pipeline by CEL-SCI Corp, H1 2018
Smallpox - Pipeline by Chimerix Inc, H1 2018
Smallpox - Pipeline by EpiVax Inc, H1 2018
Smallpox - Pipeline by SIGA Technologies Inc, H1 2018
Smallpox - Pipeline by Tonix Pharmaceuticals Holding Corp, H1 2018
Smallpox - Dormant Projects, H1 2018
Smallpox - Dormant Projects, H1 2018 (Contd..1), H1 2018
Smallpox - Discontinued Products, H1 2018

List of Figures
Number of Products under Development for Smallpox, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Targets, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

【レポートのキーワード】

天然痘

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[天然痘:治療薬開発パイプライン分析]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆